This is a preview of subscription content, log in via an institution to check access.
Reference
Rocca E, et al. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020. Drug Safety : 10 Aug 2021. Available from: URL: https://doi.org/10.1007/s40264-021-01091-x
Rights and permissions
About this article
Cite this article
Remdesivir vs tocilizumab in COVID-19: adverse event profiles. Reactions Weekly 1869, 11 (2021). https://doi.org/10.1007/s40278-021-00876-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-00876-z